MRSA is not an ordinary microbe. It is a Gram-positive bacterium that has evolved a molecular shield against the beta-lactam family of antibiotics, which includes methicillin, penicillin, and their chemical relatives. The shield comes from a gene called mecA, which encodes an altered penicillin-binding protein known as PBP2a. This modified protein has such a low affinity for beta-lactam drugs that the antibiotics simply cannot bind to it and disrupt cell-wall construction, rendering the entire drug class useless against the invader. The consequence is that infections which once yielded to cheap, widely available medicines now demand second-line or more powerful agents, driving up treatment costs, prolonging hospital stays, and increasing mortality. According to the 2019 Global Burden of Disease study, MRSA alone accounted for approximately 3.5 million disability-adjusted life years and more than 100,000 deaths worldwide, placing it among the leading causes of antimicrobial-resistance-related mortality.

The nasopharynx, the moist passage connecting the back of the nose to the throat, serves as the primary reservoir for this bacterium. People who carry MRSA there typically feel perfectly healthy, yet they shed the organism through direct contact, contaminated surfaces, and crowded living or working environments. In healthcare facilities, colonized patients and staff can seed outbreaks that are difficult to contain. In the wider community, persistent colonization raises the risk that the bacterium will eventually breach the skin or mucosal barriers and cause invasive disease, including pneumonia, sepsis, endocarditis, and severe skin and soft tissue infections. The elderly, young children, and immunocompromised individuals face the greatest danger of this progression from harmless carriage to life-threatening infection.

Despite this well-documented threat, the Ethiopian evidence base has long been fragmented. Individual studies reported carriage rates that varied wildly, from under 2 percent to more than 37 percent, and earlier regional syntheses failed to capture all available Ethiopian data. Previous meta-analyses also focused on antibiotics such as linezolid, ceftaroline, and vancomycin that are rarely available or routinely used in Ethiopian hospitals and pharmacies, making their resistance profiles of limited practical value for local clinicians. The new analysis set out to close these gaps by pooling every eligible Ethiopian study published between 2015 and 2025, focusing specifically on antibiotics that Ethiopian prescribers actually reach for, and identifying the factors that put certain people at higher risk of carrying the resistant strain.

The research team followed rigorous systematic review methodology, searching five major bibliographic databases and reporting according to PRISMA guidelines, with the protocol prospectively registered in PROSPERO. From an initial pool of 1,040 records, the investigators whittled the field down through duplicate removal, title and abstract screening, and full-text assessment to twenty qualifying studies. Each study was appraised with the Joanna Briggs Institute critical appraisal tool for prevalence research, and all included studies demonstrated moderate to good methodological quality. Every study identified MRSA using the cefoxitin disc diffusion test, a standardized laboratory technique in which a 30-microgram antibiotic disc is placed on agar inoculated with the bacterium; isolates showing an inhibition zone of 21 millimeters or less were classified as methicillin-resistant.

The headline finding was a pooled nasopharyngeal carriage rate of 7.3 percent, with a 95 percent confidence interval of 5.0 to 10.8 percent. Behind that average, however, lay enormous variability. The heterogeneity statistic, which measures how much of the observed variation among studies is due to real differences rather than chance, reached 95.5 percent, indicating that the studies differed profoundly in their populations, settings, and methods. Subgroup analysis revealed striking contrasts: carriage was highest among people living with HIV at 13.8 percent, followed by inpatients at 12.7 percent, while school children showed the lowest rate at 3.1 percent. Meta-regression confirmed that study population was the single most influential moderator, explaining 58 percent of the between-study variability, with HIV-positive individuals showing significantly elevated carriage compared with college students after adjustment.

The resistance profile of the 3,760 MRSA isolates tested across the included studies tells an equally sobering story. Tetracycline resistance topped the list at roughly 56 percent, followed by trimethoprim-sulfamethoxazole at nearly 50 percent and erythromycin at 44 percent. These are precisely the inexpensive, broad-spectrum antibiotics that dominate prescribing in Ethiopia and are freely available in informal drug outlets, a pattern that creates relentless selective pressure favoring resistant strains. Tetracycline is also used extensively in livestock production, adding an agricultural dimension to the resistance problem. By contrast, clindamycin showed the lowest pooled resistance at about 13 percent, likely reflecting its limited availability and correspondingly lower selection pressure. The authors note that these findings align with reports from other East African settings, including Kenya, where reduced susceptibility of MRSA to commonly used antibiotics has also been documented.

Perhaps most actionable are the risk factors the analysis identified. People with a history of hospitalization had more than fourfold higher odds of carrying MRSA in their nasopharynx, with a pooled odds ratio of 4.48, while those with previous antibiotic exposure had roughly 2.4-fold higher odds. These associations, consistent with meta-analytic evidence from the United States and China, point to a clear target population: anyone with recent healthcare contact or recent antibiotic use. Wounds, respiratory infections, skin lesions, and male sex, by contrast, did not reach statistical significance in the pooled analysis. The implication for public health strategy is straightforward. Screening and decolonization efforts, tightened hygiene practices, and rational antibiotic prescribing should concentrate on patients moving through hospitals and clinics, where the bacterium finds its most fertile transmission ground.

The study is not without caveats, and the authors are candid about them. Publication bias was detected through Egger’s and Begg’s statistical tests, and a trim-and-fill analysis that imputed nine missing studies raised the adjusted prevalence estimate to 14.77 percent, suggesting the true burden may be substantially higher than the headline figure. The geographic coverage of included studies was limited to a few regions, mainly Amhara, Oromia, Tigray, and the Southern Nations, Nationalities, and Peoples’ Region, which may limit national representativeness. Inconsistent definitions of risk factors across studies complicated the pooling of certain determinants, and resistance estimates for some antibiotics rested on few studies, yielding wide confidence intervals. A meta-regression across the 2015 to 2025 period found no significant temporal trend, meaning prevalence has remained stubbornly stable rather than improving.

What emerges from this analysis is a call to action grounded in context-specific evidence. The authors argue for strengthened antimicrobial stewardship programs, national surveillance systems, and targeted infection prevention and control measures aimed at high-risk groups, particularly hospitalized patients, people living with HIV, and those with recent antibiotic exposure. They also recommend that future Ethiopian studies incorporate molecular characterization of MRSA strains, including SCCmec and spa typing and detection of virulence factors such as Panton-Valentine leukocidin, to illuminate how local strains relate to global epidemic clones. For a country where second-line antibiotics remain scarce and expensive, preventing colonization in the first place is far more economical than treating resistant infections after they take hold. The quiet bacteria dwelling in Ethiopian noses may be invisible, but this research makes their scale, and the urgency of confronting them, impossible to ignore.

Subject of Research: Nasopharyngeal carriage, antimicrobial resistance patterns, and risk factors of methicillin-resistant Staphylococcus aureus in Ethiopia

Article Title: Nasopharyngeal Carriage Rate, Risk Factors, and Co‐Resistance Patterns of Methicillin‐Resistant Staphylococcus aureus in Ethiopia: Systematic Review and Meta‐Analysis

Article References: Endalamew, S. G., Kebede, S. A., Assefa, S. K., Zegeye, A. T., Abate, B. J., Asgedom, D. K., Taye, E. A., Andargie, E. M., Alemu, E. A., Kebede, H. A., Wassie, A. T., Assefa, A. Y., Ambaw, Y. G., & Alemaw, H. B. (2026). Nasopharyngeal Carriage Rate, Risk Factors, and Co‐Resistance Patterns of Methicillin‐Resistant Staphylococcus aureus in Ethiopia: Systematic Review and Meta‐Analysis. MicrobiologyOpen, 15(5), Article e70409. https://doi.org/10.1002/mbo3.70409

Image Credits: AI Generated

DOI: 10.1002/mbo3.70409

Keywords: MRSA, Ethiopia, antimicrobial resistance, nasopharyngeal carriage, systematic review, meta-analysis, Staphylococcus aureus, hospitalization, antibiotic use, tetracycline resistance, public health, infection control